The Key Technique in the mRNA Vaccine Therapy
DOI:
https://doi.org/10.54097/9d1ahr43Keywords:
mRNA Vaccine; Lipid Nanoparticles (LNP); Cancer Treatment; Infectious Diseases; Delivery; In Vitro Transcription; mRNA Modification.Abstract
mRNA-based gene therapy drugs and preventive vaccines have become a hot topic of development. The technical principle is that mRNA delivered to the body cells can be expressed through the translation mechanism of host cells to produce therapeutic proteins or immunogenic proteins, which have therapeutic effects on the body or stimulate the body to produce immune effects. mRNA vaccines have many advantages over traditional vaccines, such as their safety, flexibility, rapid production and low cost. mRNA vaccines are therefore proposed as a new frontier in vaccination. in this review, the main key technologies based on mRNA drug design, such as in vitro transcription (IVT), nucleotide and cap and tail structure modification, were reviewed, followed by a brief introduction to mRNA purification methods and delivery systems. Several novel mRNA drugs are also briefly described. Finally, the latest research directions and possible challenges of mRNA are mentioned, aiming to provide support for the development of mRNA gene therapy drugs and vaccines.
Downloads
References
[1] Brenner, S., Jacob, F., & Meselson, M. (1961). An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis. Nature, 190(4776), 576–581.
[2] Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct Gene Transfer into Mouse Muscle in Vivo. Science, 247(4949), 1465–1468.
[3] Kumar, P., Sweeney, T. R., Skabkin, M. A., Skabkina, O. V., Hellen, C. U. T., & Pestova, T. V. (2014). Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5′-terminal regions of cap0-, cap1- and 5′ppp- mRNAs. Nucleic Acids Research, 42(5), 3228–3245.
[4] Martin, S., Paoletti, E., & Moss, B. (1975). Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. Journal of Biological Chemistry, 250(24), 9322–9329.
[5] Lima, S. A., Chipman, L. B., Nicholson, A. L., Chen, Y.-H., Yee, B. A., Yeo, G. W., Coller, J., & Pasquinelli, A. E. (2017). Short poly(A) tails are a conserved feature of highly expressed genes. Nature Structural & Molecular Biology, 24(12), 1057–1063.
[6] Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, Ö., & Sahin, U. (2006). Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 108(13), 4009–4017.
[7] Hoerr, I., Obst, R., Rammensee, H.-G., & Jung, G. (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 30(1), 1–7.
[8] Carralot, J.-P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H.-G., & Pascolo, S. (2004). Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cellular and Molecular Life Sciences CMLS, 61(18), 2418–2424.
[9] Jansen, Y., Kruse, V., Corthals, J., Schats, K., van Dam, P.-J., Seremet, T., Heirman, C., Brochez, L., Kockx, M., Thielemans, K., & Neyns, B. (2020). A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunology, Immunotherapy, 69(12), 2589–2598.
[10] Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., Fotin-Mleczek, M., Hoerr, I., Clemens, R., & Sonnenburg, F. von. (2017). Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet, 390(10101), 1511–1520.
[11] Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018). Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Seminars in Immunology, 39, 14–21.
[12] Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012). Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines, 11(3), 349–366.
[13] Ramachandran, S., Satapathy, S. R., & Dutta, T. (2022). Delivery Strategies for mRNA Vaccines. Pharmaceutical Medicine, 36(1), 11–20.
[14] Cheng, X., & Lee, R. J. (2016). The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Advanced Drug Delivery Reviews, 99, 129–137.
[15] Igyártó, B. Z., & Qin, Z. (2024). The mRNA-LNP vaccines – the good, the bad and the ugly? Frontiers in Immunology, 15.
[16] Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., … Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Academic Journal of Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
